BTC Health (ASX:BTC) expanded its footprint in the high-stakes critical care market, securing an exclusive multi-year distribution agreement with global blood purification leader, Jafron Biomedical.
Under the deal, BTC’s investee company, BTC Cardio, becomes the sole Australian distributor for Jafron’s HA-series disposable hemoperfusion cartridges, specifically the HA60, HA330, and HA380 models.
The HA-series utilises advanced neutral macroporous resin technology to perform extracorporeal blood purification.
While standard dialysis is effective for clearing small water-soluble toxins, Jafron’s hemoperfusion technology is engineered to "adsorb" larger protein-bound molecules and inflammatory mediators, such as cytokines, directly from the bloodstream.
The capability is vital for clinicians managing patients with severe sepsis, acute poisoning, or hyperinflammatory "cytokine storms" where traditional filtration often falls short.
The agreement, which involves no upfront or milestone payments, allows BTC Health to integrate these specialised tools into existing intensive care unit workflows.
The cartridges are designed for versatility, capable of operating as standalone therapies or in conjunction with continuous renal replacement therapy and heart-lung circuits.
BTC Health Executive Chairman, Dr. Richard Treagus, noted that the partnership addresses a critical gap in the company’s current ICU offerings.
Following the immediate commencement of the agreement, BTC Health will pursue Therapeutic Goods Administration registration, with a phased commercial launch across Australian hospitals anticipated throughout 2026.
At the time of reporting, BTC Health's share price was $0.070.